mardi 21 février 2017

Onco Actu du 21 février 2017

1. Biologie

Step by Step: Stem Cell Approach Provides New Models for Studying How Acute Myeloid Leukemia Progresses [Memorial Sloan Kettering]

5. Traitements

Claims that ‘putting people in to hibernation’ will help cure cancers aren’t backed up by evidence [Cancer Research UK]

5.12.2 Immunothérapies - CAR-T

Critics of experimental cancer therapy just don’t get it [STAT]

5.2.2 Pharma - Fusions & Acquisitions

Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Transparency Push: EMA to Revise Policy on Document Access [RAPS]

Do President Trump’s Regulatory Freeze-Out and “1-in-2-Out” Orders Affect the Regulation of Compounding? [FDA Law Blog]

FDA Accepts Two sBLAs for Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings [ESMO]

Company-funded studies of approved drugs may not catch safety issues [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer [Roche]

5.4 Traitements - Economie

Innovations in Cancer Care: Capturing What Patients Value in the Calculus of Drug Costs [Precision Health Economics]

Generic version of top-selling lung cancer drug hits Chinese market [Pharmafile]

People with Cancer History More Likely to Change Prescriptions to Save Money [ACS]

6. Lutte contre les cancers

The Importance of Pediatric Drug Development: A Conversation with Pr. Gilles Vassal, Dr. Gregory Reaman, and Mr. Raymond Rodriguez-Torres [Friends of Cancer Research]

6.1 Observation

Macmillan warns of cancer 'survival gap' in Scotland [BBC News]

6.7 DMP, Big Data & applis

Sanger Institute's COSMIC database expands cancer cloud capabilities at the Institute for Systems Biology [Sanger Institute]

An IBM-Watson Collaboration Goes Under [In the Pipeline]